These PTCH mutations were the most influential factor in this decision, because they have been documented in up to 85% of all syndromic OKs (related to Gorlin-Goltz syndrome) and in nearly 30% of all non-syndromic Oks (9,10). Here, PTCH1 is linked to nevoid basal cell carcinoma syndrome.